维普中文期刊产品整合服务
51篇 您的检索式:作者名="Poobalan"
    题名 作者 年代 出处 被引量
1A review of chronic pain after inguinal herniorrhaphy显示文摘Poobalan AS Bruce J Smith WC 0,,01:1
2A review of chronic pain after inguinal herniorrhaphy显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
3A review of chronic pain after inguinal hemiorrhaphy 显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
4A review of chronicpain after inguinal herniorrhaphy 显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
5Effects of treating postnatal depression on mother-infant interaction and child development显示文摘Poobalan AS Aucott LS Ross L 2007British Journal of Psychiatry2007,191,5:1
6Protein expression by Aeromonas hydrophila during growth in vitro and in vivo 显示文摘Poobalane S Thompson K D Diab A 2008Microbial Pathogenesis2008,45,1:1
7A review of chronic pain after inguinal herniorrhaphy 显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
8Chronic pain and quality of life following open inguinal hernia repair显示文摘Poobalan AS Bruce J King PM 2001Br J Surg2001,88,8:1
9A review of chronic pain after inguinal herniorhaphy显示文摘Poobalan AS Brnse J Smith WC 2003Clin J Pain2003,19,1:1
10Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review显示文摘Aucott L Poobalan A Smith WC 2005Hypertension2005,45,6:1
11Effects of weight loss in overweight/ obese individuals and long-term hypertension outcomes: a systematic review 显示文摘Aucott L Poobalan A Smith WC 2005Hypertension2005,45,:1
12Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists:A systematic review显示文摘BACKGROUND Fixed ratio combinations(FRCs)of analogue basal insulin and glucagon-like peptide-1 receptor agonists are a newer addition to the therapeutic armamentarium for the management of type 2 diabetes mellitus.They reduce treatment complexity by combining two injectables in a single daily injectable,thus potentially improving adherence and persistence.Clinicians wanting to use FRCs would need to choose between members of the class.AIM To describe and contrast the glycated haemoglobin reduction of two FRCs of analogue basal insulin and glucagon like peptide-1 receptor agonist in adults with type 2 diabetes mellitus.METHODS The following Population,Intervention,Comparison,Outcome question was used for the primary analysis:Among adult patients with type 2 diabetes mellitus[P],what is the effect of iGlarLixi[I]compared to IDegLira[C]for bringing about glycaemic control(as measured by reduction in glycosylated haemoglobin)[O]?The Prisma Statement was used as a guideline for framing this systematic review.We searched PubMed,EMBASE and Cochrane library databases and Clinicaltrials.gov using various keywords and medical search headings related to type 2 diabetes mellitus,iGlarlixi,IDegLira and glycated haemoglobin A1c.RESULTS All 14 studies identified by the systematic search met the primary efficacy endpoint of reduction in glycated haemoglobin.There were no head-to-head studies between the FRCs of iGlarlixi and IDegLira,and we therefore did an indirect comparison based on a common comparator of insulin glargine U100.Both iGlarLixi and IDegLira effectively reduce glycated haemoglobin when compared to insulin glargine U100.However,using indirect comparisons,IDegLira had a greater haemoglobin A1c reducing ability(0.6%vs 0.3%).The indirect comparison is limited by the differences between the studies;the fasting blood glucose targets were slightly higher for iGlarLixi studies when compared to the IDegLira studies(4.0-5.0 mmol/L and 4.4-5.6 mmol/L),and the IDegLira study used a greater average dose of insulin glargine when compared to the iGlarLixi studies(66 U/d vs 40 U/d).CONCLUSION Both iGlarLixi and IDegLira effectively reduce glycated haemoglobin.Indirect comparisons,using insulin glargine as the common comparator,suggest that IDegLira reduces glycated haemoglobin to a greater extent than iGlarLixi.However,given the limitations of indirect comparisons,robust head to head studies and real-world data would better inform clinician choice and clinical practice guidelines.Poobalan Naidoo Celia Bouharati Virendra Rambiritch Sumanth Karamchand Barbara A Tafuto Rory F Leisegang 2021World Journal of Meta-Analysis2021,9,3:1
13A Review of chronic pain after inguinal herniorrhaphy 显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
14Effects of weight loss inoverweight/obese individuals and long - term hypertension outcomes: a systematic review显示文摘Aucott L Poobalan A Smith WC 2005Hypertension2005,45,:1
15Production and efficacy of an Aeromonas hydrophila recombinant S-Iayer protein vaccine for fish显示文摘Poobalane S Thompson K D Ardo L 2010Vaccine2010,28,20:1
16A review of chronic pain after inguinal herniorrhaphy 显示文摘Poobalan AS Bruce J Crains W 2003Clin J Pain2003,19,1:1
17Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review 显示文摘AUCOTT L POOBALAN A SMITH W C 2005Hypertension2005,45,6:1
18The prevalence of chronic chest and leg pain following cardiac surgery: a historical cohort study显示文摘Bruce J Dmry N Poobalan AS 2003Pain2003,104,1:1
19A review of chronic pain after inguinal heruiorrhaphy 显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
20A review of chronic pain after inguinal heruiorrhaphy显示文摘Poobalan AS Bruce J Smith WC 2003Clin J Pain2003,19,1:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费